Foundation models, virtual cells, AI-designed molecules, and the companies putting them to work.

Xaira's CEO and GSK's SVP of AI are on the same main stage panel. Boltz's founder is presenting alongside Novo Nordisk's VP of Computational Drug Design. NVIDIA and OpenAI are in the building. So are the startups building foundation models, virtual cells, and AI-designed therapeutics, ingredients, chemicals, and materials that didn't exist two years ago.
SynBioBeta is where the people building at the intersection of AI and biology present what they've built, and where the people funding, buying, and competing with them come to see it.